Kyverna Therapeutics Reports Q2 2026 Financial Results

What Happened

• On August 11, 2026, Kyverna Therapeutics, Inc. announced a business update and reported its financial results for the quarter ended June 30, 2026 via a press release. The company filed that press release as Exhibit 99.1 to the Form 8‑K. The filing was signed by Gregory Martini, Chief Financial Officer.

Key Details

• Filing date: August 11, 2026.
• Reporting period: quarter ended June 30, 2026 (quarterly results/earnings reported).
• Disclosure format: press release furnished as Exhibit 99.1 to the Form 8‑K.
• Form 8‑K was executed by CFO Gregory Martini (no executive departures or mergers were reported in this filing).

Why It Matters

• This 8‑K delivers Kyverna’s latest quarterly results and business update—key information for investors tracking earnings, revenue, cash runway, and program progress.
• The filing itself is a formal disclosure of those results; investors should read the attached press release (Exhibit 99.1) for the specific financial figures and management commentary.
• The 8‑K does not report other corporate actions (e.g., CEO changes, mergers or bankruptcies), so the primary takeaway is the company’s published quarterly performance and update.